Burning Rock Biotech Limited
BNRNASDAQHealthcareMedical - Diagnostics & Research
Previous close
$9.78
+$0.53 · +5.73%
BNR company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
59
Fair Value
Momentum
28
Weakening
Sentiment
52
Mixed
Risk resilience
26
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteHeadquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Yusheng Han
- Listed since
- Jun 12, 2020
- Employees
- 667
Market position
Day range
Current $9.78
52-week range
Current $9.78
- Open
- $9.40
- Previous close
- $9.25
- Volume
- 4.52K
- 0.24× average
- Average volume
- 19.1K
- Average daily volume
- Market cap
- 10.34M USD
- Beta
- 1.38
- Market reference 1
- 50-day average
- $9.2364
- +5.89% above average
- 200-day average
- $17.6301
- -44.53% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -286.28M CNY
- P/E (TTM)
- -1.17×
- P/B (TTM)
- 0.13×
- P/S (TTM)
- 0.14×
- EV / EBITDA
- 8.95×
- Earnings yield
- -36.42%
- Free cash flow yield
- -22.17%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 74.55%
- Operating margin
- -11.37%
- Net margin
- -11.53%
- Return on equity
- -10.33%
- Return on assets
- -6.74%
- Return on invested capital
- -9.28%
Financial health
- Debt / equity
- 0.1×
- Current ratio
- 2.99×
- Altman Z-score
- -6.31
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 539.57M CNY | 515.82M CNY | 537.44M CNY | 563.24M CNY | 507.86M CNY |
| Cost of goods sold | 136.65M CNY | 153.42M CNY | 174.21M CNY | 183.2M CNY | 143.72M CNY |
| Gross profit | 402.91M CNY | 362.4M CNY | 363.23M CNY | 380.04M CNY | 364.15M CNY |
| Research and development | 166.49M CNY | 232.29M CNY | 347.02M CNY | 421.87M CNY | 367.86M CNY |
| Selling, general, and administrative | 291.27M CNY | 452.54M CNY | 685.53M CNY | 938.58M CNY | 793.35M CNY |
| Operating expenses | 457.76M CNY | 719.96M CNY | 1.03B CNY | 1.36B CNY | 1.16B CNY |
| Interest income | 8.05M CNY | 12.21M CNY | 17.96M CNY | 9.46M CNY | 3.46M CNY |
| Interest expense | 30K CNY | — | — | — | 1.54M CNY |
| Depreciation and amortization | 21.76M CNY | 52.2M CNY | 133.4M CNY | 124.1M CNY | 47.77M CNY |
| Operating income | −54.85M CNY | −357.56M CNY | −669.32M CNY | −980.41M CNY | −797.06M CNY |
| Net income | −55.35M CNY | −346.63M CNY | −653.69M CNY | −971.23M CNY | −796.7M CNY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- -31.34%
- 11 comparable reports
- Latest EPS result
- -0.2
- Estimate -2.29 · Beat by 91.26%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
BNR news
BNR peers
ETFs holding BNR
Funds reporting this stock among their holdings, ordered by reported position size.
Schwab International Equity ETFSCHF19.51M0.03%69.7B USD0.03%$28.46+0.85%
Schwab Fundamental International Large Company Index ETFFNDF16.76M0.06%26.15B USD0.25%$55.84+0.83%
State Street SPDR Portfolio Developed World ex-US ETFSPDW13.35M0.03%41.92B USD0.03%$52.02+0.79%
Davis Select International ETFDINT3.67M1.38%292.47M USD0.66%$30.38+1.10%
State Street SPDR Portfolio Europe ETFSPEU363.64K0.05%741.65M USD0.07%$57.325+0.75%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA274.67K0.03%1.08B USD0.30%$102.06+0.90%
WisdomTree International Efficient Core FundNTSI234.27K0.05%497.83M USD0.26%$48.38+0.54%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX208.33K0.04%512.34M USD0.20%$55.93+0.75%Schwab International Equity ETFSCHF- Market value
- 19.51M
- Weight
- 0.03%
- AUM
- 69.7B USD
- Expense ratio
- 0.03%
- Price / 1D
- $28.46+0.85%
Schwab Fundamental International Large Company Index ETFFNDF- Market value
- 16.76M
- Weight
- 0.06%
- AUM
- 26.15B USD
- Expense ratio
- 0.25%
- Price / 1D
- $55.84+0.83%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 13.35M
- Weight
- 0.03%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
Davis Select International ETFDINT- Market value
- 3.67M
- Weight
- 1.38%
- AUM
- 292.47M USD
- Expense ratio
- 0.66%
- Price / 1D
- $30.38+1.10%
State Street SPDR Portfolio Europe ETFSPEU- Market value
- 363.64K
- Weight
- 0.05%
- AUM
- 741.65M USD
- Expense ratio
- 0.07%
- Price / 1D
- $57.325+0.75%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA- Market value
- 274.67K
- Weight
- 0.03%
- AUM
- 1.08B USD
- Expense ratio
- 0.30%
- Price / 1D
- $102.06+0.90%
WisdomTree International Efficient Core FundNTSI- Market value
- 234.27K
- Weight
- 0.05%
- AUM
- 497.83M USD
- Expense ratio
- 0.26%
- Price / 1D
- $48.38+0.54%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX- Market value
- 208.33K
- Weight
- 0.04%
- AUM
- 512.34M USD
- Expense ratio
- 0.20%
- Price / 1D
- $55.93+0.75%
Continue in GoAI
Research BNRresearch.disclaimer